



## **Symic Bio CSO Glenn Prestwich, PhD, elected to American Association for the Advancement of Science**

**SAN FRANCISCO, November 27, 2018** – Symbic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Glenn Prestwich, PhD, Chief Scientific Officer of Symbic Bio, was elected a fellow of the American Association for the Advancement of Science. Dr. Prestwich has been about encountering problems in biology and medicine and innovating solutions using chemistry for almost 50 years. His work has resulted in over 40 issued patents, 650 peer-reviewed papers, commercialization of research tools for drug discovery in cancer, and the development of biomaterials for cell therapy, wound healing and the prevention of post-surgical adhesions. Dr. Prestwich is also the Emeritus Presidential Professor of Medicinal Chemistry at University of Utah Health Sciences.

Ken Horne, CEO of Symbic Bio, describes Dr. Prestwich as a “generalist” chemist, entrepreneur, and a consummate collaborator. “He has delivered the benefits of synthetic organic chemistry to biologists for his entire career,” he says. “The award is validation of support for fundamental research and fostering an environment that enables talented researchers to commercialize their discoveries for the benefit of patients.”

Dr. Prestwich has been one of the University of Utah’s most successful and prolific entrepreneurs. Along with mentoring over 150 graduate students, post-doctoral scientists, and visiting faculty, he identifies a seminal moment in his outstanding career as creating and directing the first Entrepreneurial Faculty Scholar program at a U.S. university. Founded in 2007, this unique group at the University of Utah promotes collaboration across disciplines, the translation of academic discoveries into products that improve people’s lives, and the mentoring of faculty and student entrepreneurs.

About his election as a fellow of the American Association for the Advancement of Science, Prestwich says, “is exciting and an honor for not just me personally, but in recognition of the universities who have supported and encouraged my research career. It’s also recognition the start-up companies who have persevered in developing the commercial products that embody the true impact of this research for patients and researchers.”

### **About Symbic Bio**

Symbic Bio is a biopharmaceutical company developing novel matrix-targeting therapeutics, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symbic Bio currently has two clinical candidates: SB-061, directed at disease modification and pain management in the treatment of osteoarthritis, and SB-030, targeting the prevention of peripheral vein graft failure. In addition, Symbic Bio is investigating applications in the areas of

fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at [www.symic.bio](http://www.symic.bio), LinkedIn page at [www.linkedin.com/company/symic-bio](http://www.linkedin.com/company/symic-bio) or follow on Twitter at [www.twitter.com/symicbio](http://www.twitter.com/symicbio).

Investor Contact

[ir@symic.bio](mailto:ir@symic.bio)

Media Contacts

[pr@symic.bio](mailto:pr@symic.bio)